Frontlight ResearchEarly access
Lung cancer trials in Malaysia
22 of 24 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Kuala Lumpur, Kuantan
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Kuching, Lembah Pantai
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- George Town, Johor Bahru, Kota Kinabalu, Kuala Lumpur, Kuantan, Kuching, Petaling Jaya, Wilayah Persekutuan
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 3Active, not recruitingA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Kuala Lumpur, Kuching
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 3Taking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- George Town, Kota Kinabalu, Kuching, Putrajaya, Selangor Darul Ehsan
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - Phase 1/2Taking peopleA Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Where
- Kuala Lumpur, Kuching, Putrajaya
- Age
- 18 years and over
- People
- 315 worldwide
- Run by
- Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00 - Phase 3Not yet taking people in MalaysiaA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Cheras, George Town, Kuala Lumpur, Perai, Petaling Jaya, Shah Alam, Subang Jaya
- Age
- 18 years and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - Phase 1/2Taking peopleA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Where
- Kuching
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- BlossomHill Therapeutics
See details and how to joinNCT06706076 - Phase 2Taking peopleA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- Kuala Lumpur, Kuantan, Kuching, Petaling Jaya
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00 - Phase 3Taking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Kuala Lumpur, Petaling Jaya
- Age
- 18 years and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - Phase 2/3Taking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- George Town, Johor Bahru, Kuala Lumpur, Petaling Jaya
- Age
- 18 years and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- George Town, Johor Bahru, Kuala Lumpur
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Kuala Lumpur, Kuching, Petaling Jaya
- Age
- 18 years and over
- People
- 1,160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - Phase 1/2Taking peopleA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Kuala Lumpur, Kuala Selangor, Kuching, Singapore
- Age
- 18 years and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Jalan Pangkor, Kuala Lumpur, Kuantan, Petaling Jaya
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 3Not yet taking people in MalaysiaA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- George Town, Kuala Lumpur, Kuching
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - Phase 3CompletedStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Kuala Lumpur, Kuala Selangor, Kuching, Lembah Pantai
- Age
- 18 years and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - Phase 3Taking peopleA Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
- Where
- Kota Bharu, Kuala Lumpur, Petaling Jaya, Pulau Pinang, Selangor Darul Ehsan
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00 - Phase 3Taking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- George Town, Kuala Lumpur, Kuching, Petaling Jaya, Putrajaya, Subang Jaya
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - Phase 3Taking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- George Town, Kota Bharu, Kuala Lumpur, Kuala Selangor, Perai
- Age
- 18 years and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - Phase 1Taking peoplePhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Where
- George Town, Kuala Lumpur, Kuala Selangor, Kuching
- Age
- 18 years and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT04686305 · EU 2023-504949-31-00 - Phase 3Taking peopleLow Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
- Where
- Alor Star
- Age
- 18 years and over
- People
- 123
- Run by
- Dr Arvindran A/L Alaga
See details and how to joinNCT07050043